文献速递前列腺癌

德国IQWiG基于证据的PSA筛查评估报告

Assessment of prostate-specific antigen screening: an evidence-based report by the German Institute for Quality and Efficiency in Health Care.
PubMed 文献 · BJU Int · 2021-07-07

CONTEXT: Prostate-specific antigen (PSA) testing increases prostate cancer diagnoses and reduces long-term disease-specific mortality, but also results in overdiagnoses and treatment-related harms.…

要点

  • PSA筛查降低前列腺癌死亡和转移风险,但对全因死亡率无获益或危害。
  • PSA筛查导致大量过度诊断及不必要治疗相关危害(如尿失禁、勃起功能障碍)。
  • 假阳性PSA导致活检,相关并发症风险小但不可忽略。

核心结论

  • 基于PSA的前列腺癌筛查获益不抵其危害。
  • 未找到评估新型生物标志物、PSA衍生指标或现代影像学筛查的合格研究,这些可能改变获益-危害平衡。

研究设计与样本

  • 遵循PRISMA声明的方案导向综合文献检索,由一名或两名研究者执行,分歧共识解决。
  • 将ERSPC框架下的8项国家试验作为个体试验纳入,以进行亚组分析识别最佳筛查参数。

主要发现

  • 全因死亡率:既无获益也无危害。
  • PSA筛查与前列腺癌死亡风险降低和转移发生风险降低相关。
  • 健康相关生活质量、不良事件及假阴性筛查后果方面无差异,因缺乏合格RCT数据。
  • PSA筛查与大量过度诊断相关,导致不必要治疗(如尿失禁、勃起功能障碍)的不良下游后果。
  • 大量假阳性PSA检测导致活检,相关并发症风险小但不可忽略。

临床怎么用

  • 为德国卫生政策决策者提供基于证据的PSA筛查获益与危害评估信息。

局限性

  • 纳入研究的临床异质性和方法学局限性。
  • 缺乏健康相关生活质量、不良事件及假阴性筛查后果的合格RCT数据。
  • 未识别出评估新型生物标志物、PSA衍生指标或现代影像学筛查的合格研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Prostate-specific antigen (PSA) testing increases prostate cancer diagnoses and reduces long-term disease-specific mortality, but also results in overdiagnoses and treatment-related harms. OBJECTIVE: To systematically assess the benefits and harms of population-based PSA screening and the potential net benefit to inform health policy decision-makers in Germany. EVIDENCE ACQUISITION: We performed a protocol-guided comprehensive literature search according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement. All steps were performed by one or two investigators; any discrepancies were resolved by consensus. To allow subgroup analyses for identifying the optimal screening parameters, the eight national trials conducted under the umbrella of the European Randomised study of Screening for Prostate Cancer (ERSPC) were included as individual trials. EVIDENCE SYNTHESIS: We included a total 11 randomised controlled trials (RCTs) with a total of 416 000 study participants. For all-cause mortality, we found neither benefit nor harm. PSA screening was associated with a reduced risk of both prostate cancer mortality and the development of metastases. For the outcomes of health-related quality of life, adverse effects and the consequences of false-negative screening results there was no difference; however, this was due to the lack of eligible RCT data. Finally, PSA screening was associated with large numbers of overdiagnoses with adverse downstream consequences of unnecessary treatment (e.g. incontinence, erectile dysfunction) and large numbers of false-positive PSA tests leading to biopsies associated with a small but not negligible risk of complications. Limitations of this assessment include the clinical heterogeneity and methodological limitations of the underlying studies. CONCLUSIONS: The benefits of PSA-based prostate cancer screening do not outweigh its harms. We failed to identify eligible screening studies of newer biomarkers, PSA derivatives or modern imaging modalities, which may alter the balance of benefit to harm. PATIENT SUMMARY: In the present study, we reviewed the evidence on the PSA blood test to screen men without symptoms for prostate cancer. We found that the small benefits experienced by some men do not outweigh the harms to many more men.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Paschen U, Sturtz S, Fleer D, et al. Assessment of prostate-specific antigen screening: an evidence-based report by the German Institute for Quality and Efficiency in Health Care. BJU Int. 2021. PMID: 33961337. doi:10.1111/bju.15444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。